secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001628280-26-021176
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M
--------------------------------------------------------------------------------

- Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.
- Q4 2025 gross margin 21% (up from 15% Q4 2024), a company record; full-year gross margin 17% in line with guidance.
- Full-year 2025 net loss $5.3M (vs $0.5M loss in 2024) including $4.0M non-cash charges and $1.2M severance/facility costs.
- Adjusted EBITDA Q4 2025 $1.0M; full-year $0.3M, second consecutive profitable year on that basis; cash grew to $25.0M.
- 2026 guidance: Adjusted EBITDA $1M–$2M, positive operating cash flow; pricing increase under extended purchase agreement through Dec 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/0001628280-26-021176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/rmti-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-021176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer